Skip to main content

Table 5 EORTC QLQ-LC13 and other symptom scores during first-line chemotherapy and during MT

From: Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting

  1st Line Maintenance     
  Mean 95% CI Mean 95% CI Diff. 95% CI F-value p-value
Dyspnoea 23.0 19.9-26.0 21.2 0.0-45.4 1.73 −22.6-26.1 0.230 0.632
Coughing 31.1 27.8-34.4 26.7 21.4-32.0 4.4 −1.8-10.6 1.943 0.165
Haemoptysis 2.8 1.1-4.5 <0.1 0.0-10.5 2.8 −7.8-13.4 0.273 0.603
Sore mouth 8.0 5.5-10.4 7.0 2.9-11.1 1.0 −3.7-5.8 0.183 0.670
Dysphagia 9.1 6.8-11.4 6.1 1.7-10.6 3.0 −2.0-8.0 1.408 0.237
Peripheral neuropathy 14.9 11.8-18.0 18.8 13.7-23.9 −3.9 −9.9-2.0 1.711 0.192
Alopecia 10.2 7.3-13.0 21.7 16.6-26.8 −11.5 −17.4- -5.7 15.116 <0.001
Pain in chest 13.2 10.8-15.7 8.0 4.3-11.7 5.3 0.8-9.7 5.437 0.022
Pain in arm or shoulder 18.1 14.8-21.3 19.6 14.6-24.7 −1.6 −7.6-4.4 0.266 0.607
Pain in other parts 24.9 21.0-28.9 25.2 18.3-32.0 −0.2 −8.1-7.6 0.004 0.951
Taste Alterationsa 19.7 16.1-23.2 31.4 24.3-38.4 −11.7 −19.6- -3.7 8.442 0.004
Skin Toxicitya 18.1 15.0-21.3 16.9 12.0-21.8 1.2 −4.6-7.0 0.179 0.673
  1. 95% CI 95% confidence interval; Bold type indicates p <.05
  2. aitems from the EORTC item bank